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Abstract
The fields of phototherapy and of inorganic chemotherapy both have long histories.
Inorganic photoactivated chemotherapy (PACT) offers both temporal and spatial
control over drug activation and has remarkable potential for the treatment of cancer.
Following photoexcitation, a number of different decay pathways (both photophysical
and photochemical) are available to a metal complex. These pathways can result in
radiative energy release, loss of ligands or transfer of energy to another species, such
as triplet oxygen. We discuss the features which need to be considered when
developing a metal-based anticancer drug, and the common mechanisms by which the
current complexes are believed to operate. We then provide a comprehensive
overview of PACT developments for complexes of the different d-block metals for
the treatment of cancer, detailing the more established areas concerning Ti, V, Cr,
Mn, Re, Fe, Ru, Os, Co, Rh, Pt, and Cu and also highlighting areas where there is
potential for greater exploration. Nanoparticles (Ag, Au) and quantum dots (Cd) are
also discussed for their photothermal destructive potential. We also discuss the
potential held in particular by mixed-metal systems and Ru complexes.
Introduction
Transition metal complexes have proven success as anticancer agents.1 Photoactivated
chemotherapy (PACT) provides the opportunity for control over when and where a
drug is activated, resulting in a greater specificity of drug action. The use of an
inactive precursor or “prodrug” is an important strategy in drug targeting.2 In this
perspective, we discuss the photophysical and photochemical processes which can
occur following photoexcitation of a metal complex, and the potential of PACT for
cancer treatment shown by metal complexes. There are excellent reviews concerning
the photophysical properties of metal complexes3,4 and the potential of photoactive
metals for medicinal applications.5 The effect of light on metal complexes and the
subsequent effects on biomolecules, particularly DNA, is also well-documented.6,7
Here, we focus specifically on inorganic PACT anticancer agents, a few examples of
which we recently highlighted.8 We consider the photophysical and photochemical
properties which are desirable, discuss the activation pathways available, and
summarise the PACT potential shown by the d-block metals (see Figure 1).
4Figure 1. Table of d-block metals, coloured to demonstrate the PACT potential of
each metal, based on recent literature. Bold = well-documented photochemical
activity.3 Underlined = well-documented anticancer activity.1a Bold + underlined =
photochemical + anticancer activity.
Photomedicinal applications of the lanthanides (largely radioimmunotherapy and
photodynamic therapy)9 and the anticancer activity of the main group metals10 are
both well-documented elsewhere3 and will not be discussed, nor will the use of metal
photochemistry for diagnostic (e.g. imaging, DNA footprinting, photoaffinity
labelling) rather than therapeutic purposes.
What do metals offer for PACT?
Light can be used to alter the electronic structure of molecules, inducing changes in
both physical and chemical properties. The excited state which is generated is
typically short-lived; however, as the molecule returns to the ground state, the energy
can be dissipated in a wide variety of ways, in the form of light or heat, a chemical
modification of the structure or transferral of energy to another species. In contrast to
organic species, metals have excited states that are often easily accessible by
irradiation with visible and UVA light. Transition metal complexes with d3 and d6
electronic configurations are particularly promising, due to the favourable
photophysical properties and the relative non-lability of complexes with these
configurations. In particular, d6 transition metal complexes can be used to exemplify
the diversity of excited states that can be generated by light excitation, and the
chemistry that is associated with their generation.7
The nature of the excited states of metal complexes has been increasingly
studied in recent years and several applications have been developed exploiting their
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5photophysics and photochemistry.11 Excitation leads to electronically- and
vibrationally-excited states with the same multiplicity as the ground state. The
transitions to the excited electronic states are formally classified according to the
character of the orbitals involved in the electronic transition, as depicted in Figure 2.
Such classification is a simplification in some cases; orbitals may have mixed
metal/ligand character depending on the nature of the metal-ligand bond and,
furthermore, electronic transitions may involve more than two orbitals at a time.
Figure 2. Simplified orbital and excited-state diagram for a d6 metal complex with
octahedral coordination (strong crystal field is assumed). Each black arrow (↑↓)
represents an electron with its associated spin. Coloured arrows (↕↕↕↕) represent the
electron involved in each electronic transition. In the singlet state electrons are spin
down (↓↓↓↓), while in the triplet state they are spin up (↑↑↑↑).
Once these excited states are generated they can undergo a series of physical
radiationless processes which ultimately lead to the ground-state electronic structure;
intersystem crossing (ISC), internal conversion (IC) vibrational relaxation,
intramolecular vibrational redistribution and solvation dynamics (reorganisation of
solvent shells). Radiative processes such as fluorescence (singlet-singlet) and
phosphorescence (triplet-singlet) result in a return to the ground state, with emission
6of light of longer wavelength than was used for the excitation. Although, metal
complexes generally emit from triplet states (i.e. phosphorescence dominates), their
emissive properties differ significantly from those observed in organic chromophores.
Due to the efficient intersystem crossing promoted by the metal ion, the lifetime of
such triplet states is typically on the 50 ns – 1 μs timescale, much faster that of
classical organic compounds (ms), and their emission quantum yield is relatively
high.
Figure 3. Jabłonski energy diagram. All possible physical processes triggered by light
excitation of a d6 metal complex are represented by dotted (– – – radiationless) and
solid (——, radiative) lines.12
Photochemical reactions from a photophysically excited metal complex (ligand
dissociation, redox processes etc.) can occur at any stage during the decay back to the
ground state. The nature of the particular photochemical process is intimately related
not only to the nature of the excited state reached by the molecule upon excitation, but
also to the energy and nature of closely-lying states and to the availability of the
dynamic processes just described, which can determine the population and
depopulation of reactive states. Associating the photochemical behaviour of a d6-
metal complex with the nature of the lowest lying triplet state (T1, Figure 3) is a
7reasonable model for most long-lived (ns or longer) inorganic systems. In this way the
excited state reactivity of metal complexes can be summarized as follows:
 Metal-centred (MC) transitions {i.e. d-d or ligand-field (LF) transitions}.
These are orbitally (Laporte)-forbidden, and can also be spin-forbidden if the spin
state changes. Consequently, they give rise to weak absorptions (ε ~ 1–20 × 103
M−1cm−1) which can be masked by stronger, formally allowed charge-transfer
transitions. Since MC transitions typically populate antibonding orbitals,13 the
excited states generated often lead to bond lengthening and favour ligand
substitution. Photochemical lability is commonly a feature of complexes in which
a MC excited state is lowest in energy, such as those metal complexes which
photorelease a bioactive molecule (e.g. CO,14 NO15).
 Charge-transfer (CT) transitions {metal-to-ligand (MLCT), ligand-to-metal
(LMCT) or to-solvent (TS)}. These give rise to more intense transitions (typically
ε ~ 0.01 – 500 × 103 M−1cm−1) and can lead to redox reactions (of both the
complex and molecules in the local environment e.g. solvent) and also result in
homolytic bond cleavage, reducing the metal centre and generating radicals.
Production of radicals under biological conditions is a well-established mechanism
for causing damage to cellular components (e.g. DNA).
 Ligand-centred (LC) transitions (or interligand (IL) transitions). These
generally involve only ligand-centered orbitals and are often seen in large
delocalised systems.
Steady-state and nanosecond spectroscopic characterisation methods can determine
the nature of excited states when electronic state evolution is complete and aid
identification of the transitions involved following irradiation. Ultrafast (fs) time-
resolved techniques and computational methods show that more complex scenarios
are possible and photochemistry (e.g. bond breaking) can occur when electronic state
evolution is not complete, from both singlet and triplet states which are accessible
through excitation or radiationless processes. For multimetal complexes, there is the
possibility for additional metal-metal transfers.
For complexes in which the CT absorption band is well-separated from the
MC band, selective irradiation can often control the type of photoreaction: for
8example for CoIII, irradiation into the LMCT band typically produces photoreduction
giving rise to CoII and oxidised ligand, whereas irradiation into the MC (d-d)
irradiation causes photosubstitution/aquation.7
Desirable features of photoactivated metal-based drugs
Aspects such as aqueous solubility, cell uptake and stability in biological media are
common considerations for any potential drug. When developing photoactivatable
metal anticancer agents additional key features which should be considered include
the following.
 A large difference between cytotoxicity in the presence and absence of irradiation
is desirable in order to limit unwanted side-effects, which may also reduce drug
efficacy.
 The wavelength of activation should ideally lie within a phototherapeutic window
of 620–850 nm. This range has the maximum depth penetration into mammalian
tissue.5
 The dependence of the PACT mechanism on O2. Tumours exhibit varying levels
of oxygenation;16 low levels can reduce drug efficacy e.g. of PDT agents (which
require O2), and for some photoactive complexes different pathways are favoured
in the presence or absence of oxygen.
 The quantum yield or efficiency of the photochemical process.
Suitability of the wavelength of light for irradiation (λirr)
As highlighted above, the depth of penetration of light into tissue is important. It
depends on both the wavelength and the tissue type;17 highly pigmented tissue can
rapidly attenuate light. For activation of photochemotherapeutic compounds, the
wavelength of irradiation (λirr) depends on the properties of the photochemical agent
and the size of the tumour (and in practice, the availability of light sources). For
current clinical application the use of red light (~630 nm) is routine although for
superficial tumours shorter wavelengths e.g. blue (420 nm), may be more
appropriate.18
Multiphoton excitation is an effective way to extend the wavelength of excitation of a
metal complex.19 It imposes constraints on the structure of the compound, and the
light source needs to have a high photon density (e.g. a femtosecond laser).
9Consequently the excitation volume is much smaller than that for one-photon
excitation since two photons need to be absorbed by the molecule simultaneously.
Mechanisms of anticancer action
Although often complex, rational improvement is only possible if the mechanism of
action is at least partly understood. Where possible in this overview we highlight the
mechanism proposed.
The mechanisms of action fall into three broad categories:
1) Photodissociation and/or redox changes: causing direct reaction of the metal
with a biological agent e.g. Pt binding to DNA or protein, or photorelease of a
bioactive agent e.g. NO, CO. The term ‘photocisplatin’ reagents was coined for
rhodium (and related) metal complexes which are thermally inert, but which form
covalent bonds with DNA upon irradiation with UV or visible light.20 Different
oxidation states often exhibit different ligand binding kinetics, e.g. photoreduction
of PtIV to PtII generates a much more labile, reactive species.
2) Photosensitisation: Excited triplet states of metal complexes may be
deactivated by reaction with ground-state triplet oxygen, forming highly reactive
singlet oxygen (1Δg) (known as a type-II process). In order for this to be possible,
the energy of the excited state triplet of the metal complex must be ≥ 22.4
kcal.mol−1 compared to the ground state, since this is the excitation energy of
singlet oxygen (1O2).21 Subsequent reactions of singlet oxygen in biological
systems result in DNA damage, protein destruction, and cell lysis, destroying the
tumour.22-24 Generation of a secondary destructive species (e.g. 1O2, HO•) in this
way is known as photosensitisation, and the medical application is photodynamic
therapy (PDT).9b,21,25 For PDT applications, the singlet oxygen quantum yield ΦΔ
of a given complex is the crucial parameter which determines the efficacy of the
system; d0(MgII, AlIII) or d10 (ZnII, CdII) configurations usually have moderate to
high values of ΦΔ as do complexes of some of the heavier elements (PdII, PtII).21
Apart from the potential of the metal complex for photobleaching, this can be
considered catalytic.
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3) Photothermal reaction: Conversion of excited state energy to thermal energy
(e.g. nanoparticles, quantum dots). Due to the absence of radiative (emissive)
decay, following photoexcitation the energy is released as heat, which then
destroys the tumour.
The potential of d-block metals as photoactive anticancer complexes
Several excellent reviews have focussed on the handful of well-developed PACT
metal complexes;7,20 here we discuss the general potential shown by d-block elements
for PACT, highlighting that several photoactive metals have been scarcely
investigated for PACT applications and as such, are worthy of pursuit.
Group 3. The elements of group 3, Sc, Y and La, exist predominantly in the 3+
oxidation state. The PACT potential of Group 3 elements has not yet been
investigated.
Group 4. Of Group 4, Ti, in the form TiO2, has been studied extensively for its
photochemical properties, particularly in photocatalysis, photoelectrochemical solar
energy conversion and self-cleaning/sterilizing applications.26 Crucially, TiO2 can kill
cancer cells when irradiated with UVA light.27,28 Sadler et al. have shown that a
mononuclear citrate TiIV complex is able to undergo photoreduction (with UVA) to
TiIII; as TiIII is a strong reductant, it is capable of initiating free radical reactions in
cells.29 Although Ti is undergoing a renaissance as an anticancer agent,30 the heavier
elements Zr and Hf have been little studied in this regard.
Group 5. Chakravarty et al. are developing V-based PDT agents, achieving
photoactivation at ~800 nm (current PDT agents absorb ~630 nm), with little dark
toxicity. OxovanadiumIV complexes containing the heterocyclic bases dpq
(dipyrido[3,2-d:2’,3’-f]quinoxaline) and dppz (dipyrido[3,2-d:2’,3’-c]phenazine) have
been shown to exhibit DNA cleavage mechanisms involving both singlet oxygen and
hydroxyl radicals when activated at 365 nm, with only the HO• radical mechanism
operating when irradiated with near-IR light.31 Although VIV (d1) complexes show
similarities to CuII (d9) complexes in terms of possessing low-energy visible bands,
they do not possess the drawbacks of dark toxicity exhibited by the CuII complexes,
caused by in vivo reduction to CuI since the VIV ion in VO2+ is unlikely to undergo
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redox transformation in a biological medium.32 Others have also reported the
photochemical cleavage of DNA by V complexes.33 Currently, the medical
applications of Ta are limited to metal implants34 and the poor stability of Nb
compounds in aqueous solutions below pH 10 may explain its limited exploration to
date.35
Group 6. The photochemistry of Cr has been extensively investigated.3a [M(CO)4(α-
diimine)] complexes (where M = Cr, Mo, W and for α-diimines such as bpy) have
well-characterised photochemical properties, and undergo photochemical substitution
of an axial CO ligand when irradiated with UV or visible light.36 Although such
studies have not yet targeted medical applications, controlled CO release can be an
efficient and advantageous way of promoting cell death.37 Morrison et al. have
studied the DNA binding properties of photoactive CrIII diimine complexes such as
[Cr(phen)(Cl)2],38 which can photorelease a coordinated ligand (e.g. Cl). Ford and
coworkers have developed several CrIIINO complexes which release NO upon light
irradiation.39 In particular, the new generation complexes with antenna ligands have
improved absorption properties (λmax 650 nm) since absorption at these longer
wavelengths is useful for photoactivation in tissues.40
Both porphyrin41 and porphycene42 complexes of [O=MoV-X] show visible light
induced dissociation of the axial ligand (X) and reduction to MoIV. For X = Cl, the
quantum yields (Φ) for the homolytic bond cleavage and photochemical release of Cl•
from the porphycene complex are 0.055 (500 nm), 0.045 (600 nm) and 0.040 (650
nm). WIV polyoxometalates show promise in photoactivatable antibacterial
applications.43 However, the application of these Mo and W systems to PACT has yet
to be demonstrated.
Group 7. MnIII porphyrins show promise for PDT44 and the photorelease of CO from
Mn centres has also been demonstrated.14,45 Radioactive isotopes of both Re and Tc
are used in imaging and radiotherapy. Anticancer applications exploiting the
photochemical activity of Tc are scarce (presumably because all Tc isotopes are
radioactive, making them more hazardous to work with than Re), although Re has
been more extensively investigated.3,46
Group 8. This group offers examples of photosensitizers, intercalators, DNA binders
and complexes able to photorelease bioactive ligands. Two-photon excitation (2PE)
leading to NO release has been explored in depth for Fe nitrosyls,47 and recently
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Prasad et al. have reported two-photon excitable, water-soluble Fe (NO) release
agents which show dark toxicity but which exhibit a slight phototoxic enhancement in
HeLa cells.48 Irradiation of a FeIII triazine complex (72 hr, λirr ≥ 455 nm) creates a
LMCT excitation, generating a highly oxidising, charge-separated excited state (Fe2+-
ligand radical). The triazine radical thus generated is capable of cleaving plasmid
DNA by an oxygen-independent pathway, and subsequently decomposes to give N2.49
An FeIII complex of dpq (selected for its DNA binding properties) and the tetradentate
(2,2-bis(3,5-di-tert-butyl-2-hydroxybenzyl)aminoacetic acid)] ligand (which stabilizes
the +3 state) causes DNA nicking following irradiation (λirr ≤ 647 nm), again, due to
the generation of a charge-separated excited state.50 The mechanism of cleavage is
oxygen-dependent, but operates through a superoxide O2•-and HO• radical mechanism
rather than by 1O2 generation. Related work has demonstrated oxo-bridged diiron
complexes of dpq which are capable of photocleaving bovine serum albumin (λirr 365
nm), again, via the HO• radical pathway.51
The photophysics and photochemistry of Ru has been extensively studied.
Both RuIII and RuII show potential; RuIII complexes are reasonably inert to ligand
substitution and can be activated by reduction to RuII, which can then react either
thermally or photochemically with DNA. The dinuclear complex [{(η6-
indan)RuCl}2(μ-2,3-dpp)](PF6)2 undergoes arene loss via an oxygen-independent
pathway when irradiated (λirr = 365 nm), releasing a fluorescent marker (indan) and
creating a highly reactive Ru species capable of forming both mono- and bifunctional
adducts of DNA.52 The use of π-acceptor ligands such as TAP (1,4,5,8-
tetraazaphenanthrene) and HAT (1,4,5,8,9,12-hexaazatriphenylene) in RuII complexes
shows much photochemical potential and is discussed in the Highlights section.53
Os offers both a rich photochemistry3b and promise in the anticancer field54 but most
PACT investigations using Os have been in mixed-metal systems (see Highlights
section). The high thermal stability of OsII complexes can make syntheses
challenging, but the final product is also more robust to degradation. Promisingly, Os
complexes possess low energy MLCT bands55 and the design aspects of DNA
cleaving complexes involving Os have been considered, paving the way for
development of PACT applications.56
Group 9. CoIII complexes are usually substitution-inert. Thermal or photochemical
reduction to the more kinetically labile CoII can induce selective ligand release.
Thermal (e.g. hypoxia-activated)57 release is exemplified by a CoIII complex of the
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matrix metalloproteinase inhibitor Marimastat, a combination which shows excellent
anticancer activity.58 Photochemical release has also been used to deliver a therapeutic
agent, for example, cis-[CoL(NO2)(ONO)]+ (L = 6-(anthracen-9-ylmethyl)-1,4,8,11-
tetraazacyclotetradecane) releases NO (which sensitises hypoxic tissue to γ-
radiation59) upon irradiation (λirr = 360 nm).60 Photoreduction is also seen for CoIII
and several complexes have been shown to photocleave DNA;61 McFadyen et al. have
shown that [CoIII(en)2(dppz)]3+ photocleaves DNA (λirr = 350–400 nm). The
mechanism involves reductive quenching of the CoIII* excited state by bases e.g.
guanosine (G), producing a radical cation G•+ which eventually results in cleavage of
the DNA backbone. Although phototoxicity has been demonstrated in cellulo, the
complex also exhibits considerable dark toxicity.62 Stereospecific photocleavage of
DNA using chiral CoIII complexes is well-established,63 and in general Co holds
considerable potential for future PACT developments.
The photochemistry of RhIII complexes is determined by the nature of the
lowest lying state. In bis-chelated (polypyridyl) RhIII complexes this is typically a
3MC state; photoexcitation weakens the M–L bond, resulting in photosubstitution. In
contrast, excitation of the lowest lying state (3LC) in the tris-chelated (polypyridyl)
analogues creates a strong oxidising agent. The complex cis-[Rh(phen)2Cl2]+
illustrates the dependence of the photochemistry on the presence of various species;
O2 quenches photoaquation of this species, with formation of singlet oxygen – but the
quantum efficiency for photoaquation is increased by the presence of deoxyguanosine
(dG), possibly due to reductive quenching.7 The excited states of RhIII polypyridyl
complexes tend to be more strongly oxidising than their RuII counterparts, resulting in
more efficient reactions for DNA damage. RhIII complexes are relatively thermally
inert, but may undergo efficient photosubstitutions, making them potentially useful
for PACT. However, in contrast to their RuII counterparts, mononuclear RhIII
complexes show little absorption (e.g. MC or CT bands) in the visible region of the
electronic spectrum – instead, the spectrum is dominated by intense LC bands in the
UV region.7 Despite this, Morrison et al. have shown that methylated derivatives of
[cis-Rh(phen)2Cl2]Cl such as OCTBP (see Figure 4) can be activated at wavelengths
where there is no apparent absorption, (λirr > 500 nm) due to the direct population of
weakly absorbing 3MC states by photoexcitation from the ground state; these
complexes exhibit moderate phototoxicity in tumour cells.64 Barton et al. have
pioneered the use of complexes such as [Rh(bpy)2(chrysi)]3+ which targets single base
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DNA mismatches, and upon photoactivation (λirr ~ 340 – 450 nm) cleaves the DNA
next to the mismatch.65 This shows potential for PACT since the inability of cells to
control and regulate mismatch repair is implicated in several cancers.66 Dinuclear Rh
complexes allow extension of the possible wavelength of activation;67 the
cytotoxicity of cis-[Rh2(μ-O2CCH3)2(CH3CN)]2+ (Figure 4) increases 34 times upon
irradiation, with an LC50 ~12μM in human skin cells when irradiated (λirr = 400–700
nm).68
Ir complexes exhibit a rich photochemistry,69 however, most photobiological
applications focus on the luminescent properties70 and the PACT potential of Ir
complexes remains relatively unexplored.
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Figure 4. (a) OCTBP, a methylated [cis-Rh(phen)2(Cl)2]Cl derivative which shows
phototoxicity towards tumour cells (λirr> 500 nm). (b) dinuclear Rh complex which
shows 34 x increase in cytotoxicity when irradiated (λirr = 400–700 nm) (c) Pd-based
PDT agent TOOKAD currently in clinical trials (structure adapted from reference 71).
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Group 10. Although Ni complexes have been investigated as anticancer agents,72
only a few investigations consider photoactivity;73 for example,
[Ni(bpy)2(benzo[1.8]naphthyridinone-2-ol)](PF6)2 binds to DNA in the absence of
irradiation, and upon irradiation (λirr 365 nm) photocleaves the DNA through a
mechanism involving both 1O2 and HO• radicals.74
Both common oxidation states of Pt show a rich photochemistry;75 many PtII
complexes luminesce following irradiation, due to long-lived excited states76 while
the photochemistry of PtIV complexes is dominated by dissociative/reductive
behaviour. In collaboration with others we have investigated the photochemistry of a
range of PtIV diazido complexes, in an effort to develop selective PACT agents.75,77
Briefly, irradiation of the complexes into either the LMCT bands (λirr = 365 nm) or
the weaker d-d transitions at longer wavelengths (λirr = 420, 514 nm) can cause
photodissociation and/or photodecomposition of the azido ligands and reduction of
the PtIV centre to PtII. When the irradiation is undertaken in cell culture, a potent
cytotoxic effect is seen, which is not observed either in the dark, or with irradiation of
the cells in the absence of the Pt complex. For the PtIV complexes –– irradiation at
wavelengths where there appears to be essentially no absorbance in the electronic
spectrum can still result in photoactivity77a (as observed for Morrison’s Rh
complexes)64 due to the direct excitation of dissociative low-lying LMCT states (e.g.
S1−S4, Figure 5a). Time-dependent DFT calculations show that such transitions
involve σ-antibonding orbitals (Figure 5b) which favour ligand dissociation once
populated.
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Figure 5. (a) Calculated (TDDFT) and experimental absorption spectrum of
cis,trans,cis-[Pt(N3)2(OH)2(NH3)2] in H2O. The excited states are shown as vertical
bars with heights equal to their extinction coefficients. Transitions S1−S4 have all
dissociative character since they involve (b) the σ-antibonding orbitals LUMO and
LUMO+1.
Clearly the action spectrum does not mirror the UV-vis electronic spectrum
for these complexes. The use of weaker field donors such as iodide instead of azide
typically results in dark toxicity due to thermal reactions with biological reductants
(e.g. glutathione).77f Extension of the wavelength of activation of these complexes is a
balance between thermal stability and activation with the longest wavelengths
possible. In other research, the combination of a phototoxic porphyrin with a
cytotoxic Pt unit within the same molecule has been investigated,78 but in general the
photochemistry of the Pt centre itself remains largely unexploited for PACT
applications.
A PDT photosensitiser containing Pd (TOOKAD)79 is in Phase I/II clinical trials for
treatment of prostate cancer (see Figure 4); the complex can be photoactivated to
produce 1O2 (λirr = 762 nm, diode laser) and shows rapid clearance from the body, an
advantage over conventional PDT agents, which can cause prolonged photosensitivity
of the patient following treatment. Contrastingly, a paramagnetic, non-emitting Pd-
phthalocyanin complex has shown promise for photothermal therapy (PTT) since it
shows considerable absorption at near–IR wavelengths (826 nm);80 in PTT tumour
cells are killed by the heat generated from the efficient radiationless decay to ground
state of such a Pd derivative.
Group 11. Cu complexes such as [CuII(2-(2-pyridyl)benzthiazole)Br2] have been
shown to oxidatively cleave DNA in the presence of O2 without direct irradiation,81
others only cleave DNA upon irradiation,82 with complexes such as [CuII(dppz)((L-
lysine)(OClO3)] being activated to cleave DNA with near-IR light by a mechanism
involving 1O2 (λirr 700 – 755 nm).83 Binuclear copper complexes [{(R)CuII}2(μ-
dtdp)2] (where R = phen or dpq and H2dtdp = 3,3’-dithiodipropionic acid) reportedly
cleave DNA when irradiated (λirr = 753 – 799 nm) both in the presence of O2 (through
1O2 and HO• pathways) but also in the absence of O2, due to the generation of sulfur
anion radicals.84 It will be of interest to see whether this translates to
photocytotoxicity in cellulo or indeed, in vivo.
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Irradiation of Ag complexes in the presence of DNA results in metallation but not
cleavage,85 and although Ag compounds are often photosensitive little PACT research
has been conducted. In contrast, Au compounds are well-known for their anticancer
potential;86 if the dark cytotoxicity of AuIII porphyrins87 can be controlled, then AuIII
tetraarylporphyrins have potential in PDT.3 The alternative technique of photothermal
ablation uses irradiation of gold (or silver) nanoparticles to achieve a cytotoxic
effect;88 the absorption of light by the nanoparticles induces localised surface plasmon
oscillations, the electrons resonate in response to incoming radiation, causing them to
both absorb and scatter light. The light is rapidly converted into heat which destroys
the immediate tissue. The use of targeting features such as Paclitaxel (Taxol),89
Herceptin90 or transferrin91 conjugated to nanoparticles enables targeting, imaging and
therapy for cancer cells, all with a single agent. Gold nanoparticles have also been
shown to cleave DNA upon irradiation (aerobic conditions) with UV (λirr = 312 nm)
light.92
Group 12. Aside from the use of Zn-porphyrin and Zn-phthalocyanine derivatives in
PDT,21 Cd-based quantum dots (QD) represent the most promising development of
group 12 for PACT application.93 QD can be used to generate reactive radicals to kill
tumours, at the same time offering highly tunable absorption and emission
properties.94 QD which are activated by X-ray – behaving as a PDT agent as well as a
fluorescent marker – are particularly promising.95 Explorations of Hg photochemistry
do not appear to have been applied yet to biological systems, presumably for toxicity
reasons.96
Highlights
In the following section we consider the potential offered by mixed-metal systems and
Ru complexes.
 Mixed-metal systems
Combining different metals in a multinuclear complex is a powerful way to exploit
the (photo)chemical properties of each metal, in a synergistic fashion.
Work on trinuclear complexes [{(bpy)2M(dpp)}2RhCl2]Cl5 (where M = Ru or Os and
dpp = 2,3-bis(2-pyridyl)pyrazine, Figure 6) has highlighted that complexes which
demonstrate DNA photocleavage (e.g. where M = OsII) do not necessarily exhibit
photocytotoxicity in mammalian cell lines.97 In contrast, the RuII analogue showed
evidence of cell death for concentrations ≥ 10 μM following irradiation (λirr > 460
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nm) with no cytotoxic activity in the dark. The mechanism of the phototoxic effect
involves 1MLCT excitation of the RuII followed by conversion to a low-lying reactive
3MMCT state in which charge transfers from RuII – via a bridging π-ligand – to RhIII;
the latter acts as an electron acceptor and subsequently cleaves DNA, demonstrating
activity both in the presence and absence of oxygen. The analogous system in which
Rh is substituted for Ir showed no DNA photocleavage in vitro;98 promising variants
involving Pt are being developed.99 In other work, the mixed-metal system
[{RuII(tpm)(dppz)}(μ-dpp[5]){fac-(CO)3ReI(dppz)}]3+ (tpm = tris(1-
pyrazolyl)methane, dpp[5] = 4,4’-dipyridylpentane) combines the strong DNA
binding ability of the RuII with the DNA photocleavage ability of the ReI centre.
Activation (λirr = 355 nm) results in both single- and double-strand cleavage of
pBR322 plasmid DNA.100 A potential drawback of some multimetal systems is that a
high formal charge is thought to make cell uptake of such complexes more
challenging; complexes with lower overall charges which have not been
photobiologically investigated may prove promising in this regard.101 However it is
notable that some multinuclear PtII complexes with high charge (e.g. BBR3464, 4+
charge) can readily enter cells, so pathways for the transport of charged species into
cells do exist.
Figure 6. Mixed metal Ru-Rh-Ru complex of Brewer et al.
 Polyazaaromatic RuII complexes: photoactive molecules for a gene
silencing approach in chemotherapy
Kirsch-De Mesmaeker and coworkers have recently developed a new class of
RuII polyazaaromatic complexes containing TAP and HAT ligands, which can
selectively form photoadducts with DNA bases and amino acids when their MLCT
state is excited.102
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Although many RuII polypyridyl complexes have both oxidizing and reducing
properties in the excited state, Ru-TAP and Ru-HAT complexes show a more
pronounced oxidizing character. When excited with visible light the complexes
reported in Table 1 are able to react with DNA bases or oligomers and aminoacids
such as tyrosine (Tyr) and tryptophan (Trp), resulting in a series of redox reactions
which eventually lead to the formation of photoproducts.
Table 1. Ground-state and excited-state potentials of the first reduction wave (vs.
SCE, acetonitrile) for selected polyazaaromatic RuII derivatives
Complex Ered (V/SCE) E*red(V/SCE)
[Ru(HAT)3]2+
[Ru(TAP)3]2+
[Ru(HAT)2(phen)]2+
[Ru(HAT)2(bpy)]2+
[Ru(TAP)2(phen)]2+
[Ru(TAP)2(bpy)]2+
[Ru(TAP)2(dppz)]2+
−0.62
−0.75
−0.66
−0.76
−0.83
−0.83
−0.80
+1.49
+1.30
+1.25
+1.17
+1.15
+1.10
+1.20
Biomolecule Ered (V/SCE)
GMP
Tyr
Trp
+1.05
−0.85
−0.78
The potentials were obtained as described in reference 102.
For example, in the presence of a guanine residue (G) from guanosine-5’-
monophosphate (GMP) or DNA, [Ru(TAP)2(L')]2+ complexes can undergo the
following reactions (where * represents an excited state):
[Ru(TAP)2(L')]2+ + hν → [Ru(III)(TAP●−)(TAP)(L')]2+* (1)
[Ru(III)(TAP●−)(TAP)(L')]2+* + G → [Ru(II)(TAP●−)(TAP)(L')]1+ + G●+ (2)
[Ru(II)(TAP●−)(TAP)(L')]1+ + G●+ → [Ru(TAP)2(L')]2+ + G (3)
G●+ → G(−H)● + H+ (4)
[Ru(II)(TAP●−)(TAP)(L')]1+ + H+ → [Ru(II)(TAP+H)●(TAP)(L')]2+ (5)
[Ru(II)(TAP+H)●(TAP)(L')]2+ + G(−H)● → photoproduct (6)
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Steady-state and time-resolved studies103 have highlighted that the direct (2) and back
(3) electron-transfer process from G is likely to occur through a proton-coupled
electron-transfer mechanism (4 and 5). Two TAP and HAT ligands are necessary to
achieve oxidation of GMP, while only the highly oxidizing complexes [Ru(TAP)3]2+
and [Ru(HAT)3]2+ can react with adenosine-5’-monophosphate (AMP). In the
photoproduct obtained from the reaction between Ru-TAP and Ru-HAT complexes,
the guanine is covalently linked to the complex by the exocyclic amino group of the
base, which substitutes a H atom in the polyazaaromatic ligand ring (TAP: α-position
with respect of the non-coordinating nitrogen, Figure 7.)
Figure 7. Photoadduct formation during the photoirradiation of [Ru(TAP)3]2+ in the
presence of GMP. The photoproduct is obtained after several steps of purification and
acidification.
In addition to the photochemistry described, Ru-TAP and Ru-HAT derivatives also
damage DNA by 1O2 photosensitization. However, the photoinduced electron transfer
process that leads to the formation of stable and specific photoproducts makes this
class of complexes potential candidates in PACT, where they can exploit a novel
mechanism of action.
In fact, oligonucleotides hybridized with oxidizing Ru polyazaaromatic complexes
can irreversibly form photo-induced cross-links with a target strand. This strategy can
be used to develop specific anticancer agents based on gene silencing (inhibition of
gene expression).
Synthetic oligodeoxynucleotides (ODNs) have been used for gene expression,
targeting either double-strand DNA (antigen strategy) or single-strand mRNA
(antisense strategy). Their application has been limited by the poor stability of the
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ODN-DNA/mRNA aggregates and by the activity of enzymes that can recognize and
destroy such aggregates.104
Modified ODNs with anchored Ru-TAP and Ru-HAT complexes (Ru-ODNs) can be
successfully employed to increase the stability of the ODN aggregates. The Ru-ODN
complexes are activated by light and form strong cross-links between the ODN strand
and a guanine residue (G) on the target sequence. The so-formed adducts have
improved stability and are more resistant to enzyme action.
Several different Ru-ODNs have prepared by attaching covalently one ruthenium
polyazaaromatic unit to timidine residues or to the 5'-terminal phosphate group. All
these Ru-ODNs have been tested in the presence of their target sequence under light
irradiation with the aim of assessing the general principle governing the photoadduct
formation.
The percentage of photocross-links is determined by the ionization potential of G (e.g.
GG sites exhibit higher reduction oxidation potentials than G sites) and by the
distance between the Ru complex and G. Therefore, a minimum distance is required
to have a good photocross-linking percentage, otherwise only fluorescence quenching
occurs.
Until recently, it was considered necessary to avoid Ru-ODNs containing G to reduce
self-inhibition. However, the same authors have developed Ru-ODNs containing
guanine residues (Ru-ODN(G)), which are able to self-inhibit when irradiated in the
absence of the complementary target strand or in the presence of non-complementary
strands (Figure 8).105 In both cases cycRu-ODN(G) photoadducts are formed. In the
case of non-complementary (containing G as well) strands self-inhibition reaches an
80 % yield.
On the contrary, when a complementary strand is added and the Ru-ODN(G) is
irradiated, selective formation of inter-strand photo-crosslinks is observed and no self-
inhibition. The selectivity towards inter-strand adducts in the presence of a
complementary target strand can be explained by the increased rigidity of the duplex.
The improvement obtained with the Ru-ODNs(G) is relevant for in vivo gene silencing
applications, since it reduces the possibility of secondary photoeffects (as for example
seen with proteins).
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Figure 8. Schematic representation of the behaviour of Ru-ODN(G) (a)in the absence
of complementary strands, (b) in the presence of non-complementary strands, and (c)
in the presence of complementary target strands (adapted from reference [105]).
Outlook
Platinum complexes have a proven track record of being well suited to the treatment
of cancer and those of other transition metals have much potential. Photoactivation
provides scope for another dimension – one of highly controllable activity – of more
potent, highly targeted drugs with reduced side-effects.
The availability of a wide array of different metals, each with unique
photophysical and photochemical properties gives a broad spectrum from which to
choose. This spectrum dramatically widens once the multitude of possible ligands
(and ligand arrangements) are considered and the potential for tuning the
photochemistry is further expanded by combining several metals within the same
complex.
The photoactivation pathways taken by metal complexes can be complicated,
and can vary depending on the conditions, e.g. solvent, presence/absence of oxygen,
possible reactants (e.g. DNA/proteins) and on the wavelength of light used. Many
elegant techniques have been developed by the photochemical community in order to
better understand and therefore control the photochemistry of such systems. These
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include measurements of action spectra, singlet oxygen quantum yields and the use of
TD-DFT and ultrafast (fs) time-resolved techniques (e.g. IR) to characterise the
excited states and photochemical pathways more accurately. It is anticipated that
future improvements in X-ray time-resolved techniques will help to determine
transient structures and to validate computational results.
Understanding the variation of the photochemistry in vitro, in cellulo and in
vivo is crucial to the development of potential PACT drugs. It has been demonstrated
that reactions with biomolecules (e.g. DNA scission in vitro) does not necessarily
correspond to the desired biological action in cellulo, and it is anticipated that the
translation to in vivo testing will provide an even greater challenge (not least, because
of the need to synchronise and optimise arrival of the photoactive complex at the
target site with irradiation). Whereas the photophysics and photochemistry of some
metal systems (e.g. the Ru pyridyl complexes) have been investigated in detail, there
is still much room for exploration in this young and promising field.
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